BioVie (BIVI) 10-Q 8 Feb 22 2022 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Dec. 31, 2021	Feb. 04, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2021
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--06-30
Entity File Number	001-39015
Entity Registrant Name	BIOVIE INC.
Entity Central Index Key	0001580149
Entity Tax Identification Number	46-2510769
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	9120 Double Diamond Parkway Suite 1400
Entity Address, City or Town	Reno
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89521
City Area Code	(775)
Local Phone Number	888-3162
Title of 12(b) Security	Class A Common Stock, par value $0.0001 per share
Trading Symbol	BIVI
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		24,984,063

Condensed Balance Sheets (Unaud

Condensed Balance Sheets (Unaudited) - USD ($)	Dec. 31, 2021	Jun. 30, 2021
CURRENT ASSETS:
Cash	$ 30,391,675	$ 4,511,642
Other assets	154,868	93,487
Total current assets	30,546,543	4,605,129
OTHER  ASSETS:
Intangible assets, net	981,161	1,095,849
Goodwill	345,711	345,711
Total other assets	1,326,872	1,441,560
TOTAL ASSETS	31,873,415	6,046,689
CURRENT LIABILITIES:
Accounts payable and accrued expenses	1,663,089	996,374
Current portion of other liabilities	580,625
Warrant liabilities	896,959
Embedded derivative liability	1,217,765
Total current liabilities	4,358,438	996,374
Other liabilities	338,698
Note Payable net of financing costs and unearned premium and  discount ($3,888,813)	11,111,187
TOTAL LIABILITIES	15,808,323	996,374
STOCKHOLDERS’ EQUITY:
Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding
Common stock, $0.0001 par value; 800,000,000 shares authorized at December 31, 2021 and June 30, 2021, respectively; 24,984,083 and 22,333,324 shares issued and outstanding at December 31, 2021 and June 30, 2021, respectively	2,496	2,232
Additional paid in capital	251,903,088	229,933,505
Accumulated deficit	(235,840,492)	(224,885,422)
Total stockholders’ equity	16,065,092	5,050,315
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 31,873,415	$ 6,046,689

Condensed Balance Sheets (Una_2

Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Dec. 31, 2021	Jun. 30, 2021
Statement of Financial Position [Abstract]
Preferred Stock, Par Value	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized	800,000,000	800,000,000
Common Stock, Shares, Issued	24,984,083	22,333,324
Common Stock, Shares, Outstanding	24,984,083	22,333,324

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
OPERATING EXPENSES:
Amortization	$ 57,344	$ 57,344	$ 114,689	$ 114,688
Research and development expenses	4,591,432	938,101	7,437,026	1,063,112
Selling, general and administrative expenses	2,016,234	2,067,920	4,660,579	2,272,320
TOTAL OPERATING EXPENSES	6,665,010	3,063,365	12,212,294	3,450,120
LOSS FROM OPERATIONS	(6,665,010)	(3,063,365)	(12,212,294)	(3,450,120)
OTHER (INCOME) EXPENSE:
Change in fair value of derivative liabilities	(1,555,254)		(1,555,254)	(8,279,919)
Interest expense	316,263	143	317,378	559,455
Interest income	(11,702)	(5,701)	(19,348)	(5,765)
TOTAL OTHER EXPENSE (INCOME), NET	(1,250,693)	(5,558)	(1,257,224)	(7,726,229)
NET (LOSS)/INCOME	(5,414,317)	(3,057,807)	(10,955,070)	4,276,109
Deemed dividends - related party				53,598,320
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	$ (5,414,317)	$ (3,057,807)	$ (10,955,070)	$ (49,322,211)
NET LOSS PER COMMON SHARE
- Basic	$ (0.22)	$ (0.22)	$ (0.45)	$ (4.95)
- Diluted	$ (0.22)	$ (0.22)	$ (0.45)	$ (4.95)
WEIGHTED AVERAGE NUMBER OF COMMON  SHARES OUTSTANDING
- Basic	24,962,373	13,916,164	24,344,545	9,965,599
- Diluted	24,962,373	13,916,164	24,344,545	9,965,599

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net (loss)/income	$ (10,955,070)	$ 4,276,109
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Amortization of intangible assets	114,689	114,688
Stock based compensation - restricted stock	384,454
Stock option based compensation expense	3,074,384	1,536,929
Amortization of financing costs	14,185
Accretion of unearned loan discount	133,454	537,275
Accretion of loan premium	23,611
Change in fair value of embedded derivative liability	(995,701)	(2,225,798)
Change in fair value of warrant liability	(559,553)	(6,054,121)
Changes in operating assets and liabilities:
Other assets	(61,381)	348,528
Accounts payable and accrued expenses	666,715	(936,778)
Other liabilities	919,323
Net cash used in operating activities	(7,240,891)	(2,403,168)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of common stock	18,511,009	15,628,010
Payment of convertible debenture - related party		(1,821,818)
Proceeds from convertible debenture - related party		436,000
Proceeds from note payable net of financing costs	14,609,915
Net cash provided by financing activities	33,120,924	14,242,192
Net increase in cash	25,880,033	11,839,024
Cash, beginning of period	4,511,642	37,195
Cash, end of period	30,391,675	11,876,219
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest	146,128	22,180
Cash paid for taxes
SCHEDULE OF NON-CASH FINANCING ACTIVITIES:
Deemed dividends - related party		$ 53,598,320

Condensed Statements of Changes

Condensed Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Jun. 30, 2020	$ 520	$ 19,538,742	$ (41,037,898)	$ (21,498,636)
Beginning Balance, Shares at Jun. 30, 2020	5,204,392
Proceeds from issuance of common stock, net cost of  $2,224,992	$ 180	15,627,830		15,628,010
Stock Issued During Period, Shares, New Issues	1,799,980
Redemption of warrants  - related party	$ 155	13,132,230		13,132,385
[custom:RedemptionOfWarrantsAndPurchaseOptionRelatedPartyInShares]	1,549,750
Deemed dividend for purchase option - related party	$ 536	53,597,784	(53,598,320)
[custom:DeemedDividendForPurchaseOptionRelatedPartyInShares]	5,359,832
Cashless exercise of options
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	2,210
Net Loss			7,333,916	7,333,916
Ending balance, value at Sep. 30, 2020	$ 1,391	101,896,586	(87,302,302)	14,595,675
Ending Balance, Shares at Sep. 30, 2020	13,916,164
Beginning balance, value at Jun. 30, 2020	$ 520	19,538,742	(41,037,898)	(21,498,636)
Beginning Balance, Shares at Jun. 30, 2020	5,204,392
Stock option based compensation				1,536,929
Ending balance, value at Dec. 31, 2020	$ 1,391	103,433,515	(90,360,109)	13,074,797
Ending Balance, Shares at Dec. 31, 2020	13,916,164
Beginning balance, value at Sep. 30, 2020	$ 1,391	101,896,586	(87,302,302)	14,595,675
Beginning Balance, Shares at Sep. 30, 2020	13,916,164
Net Loss			(3,057,807)
Stock option based compensation		1,536,929		1,536,929
Ending balance, value at Dec. 31, 2020	$ 1,391	103,433,515	(90,360,109)	13,074,797
Ending Balance, Shares at Dec. 31, 2020	13,916,164
Beginning balance, value at Jun. 30, 2021	$ 2,232	229,933,505	(224,885,422)	5,050,315
Beginning Balance, Shares at Jun. 30, 2021	22,333,324
Proceeds from issuance of common stock, net cost of  $2,224,992	$ 259	18,510,750		18,511,009
Stock Issued During Period, Shares, New Issues	2,592,000
Net Loss			(5,540,753)	(5,540,753)
Stock option based compensation		$ 1,926,962		$ 1,926,962
Stock based compensation - restricted stock	3	286,756		286,759
Stock based compensation - restricted stock, Shares	37,049
Ending balance, value at Sep. 30, 2021	$ 2,494	$ 250,657,973	$ (230,426,175)	$ 20,234,292
Ending Balance, Shares at Sep. 30, 2021	24,962,373
Beginning balance, value at Jun. 30, 2021	$ 2,232	229,933,505	(224,885,422)	5,050,315
Beginning Balance, Shares at Jun. 30, 2021	22,333,324
Stock option based compensation				3,074,384
Ending balance, value at Dec. 31, 2021	$ 2,496	251,903,088	(235,840,492)	16,065,092
Ending Balance, Shares at Dec. 31, 2021	24,984,083
Beginning balance, value at Sep. 30, 2021	$ 2,494	250,657,973	(230,426,175)	20,234,292
Beginning Balance, Shares at Sep. 30, 2021	24,962,373
Net Loss			(5,414,317)	(5,414,317)
Stock option based compensation		$ 1,147,422		$ 1,147,422
Stock based compensation - restricted stock	2	97,693		97,695
Stock based compensation - restricted stock, Shares	21,710
Ending balance, value at Dec. 31, 2021	$ 2,496	$ 251,903,088	$ (235,840,492)	$ 16,065,092
Ending Balance, Shares at Dec. 31, 2021	24,984,083

Condensed Statements of Chang_2

Condensed Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) (Parenthetical) - USD ($)	3 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Statement of Stockholders' Equity [Abstract]
[custom:ProceedsFromIssuanceOfCommonStockNetOfCost]	$ 2,224,992	$ 2,371,790

Background Information

Background Information	6 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Background Information	1. Background Information BioVie Inc. (the “Company” or “we” or “our”) is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. In liver disease, our Orphan Drug candidate BIV201 (continuous infusion terlipressin) is being developed as a future treatment option for patients suffering from ascites and other life-threatening complications of advanced liver cirrhosis caused by NASH, hepatitis, and alcoholism. The initial target for BIV201 therapy is refractory ascites. These patients suffer from frequent life-threatening complications, generate more than $5 billion in annual treatment costs, and have an estimated 50% mortality rate within 6 to 12 months. The US Food and Drug Administration (FDA) has not approved any drug to treat refractory ascites. A Phase 2a clinical trial of BIV201 was completed in 2019, and a multi-center, randomized 30-patient Phase 2b trial is currently underway. As of December 31, 2021, ten of the thirteen planned US study centers had been activated and are actively screening patients, and multiple patients have been enrolled in the study. The FDA has communicated to us that pending positive Phase 2 study results, a sufficiently large and well-controlled Phase 3 trial, with supportive trend data from the Phase 2b, could potentially yield the clinical data needed to apply for BIV201 marketing approval. The Phase 2b clinical trial protocol is summarized on www.clinicaltrials.gov, trial identifier NCT04112199. Top-line results from this trial are expected in mid-2022, to be followed by a proposed single pivotal Phase 3 clinical trial beginning in late 2022, subject to favorable FDA review. The BIV201 development program was initiated by LAT Pharma LLC. On April 11, 2016, the Company acquired LAT Pharma LLC and the rights to its BIV201 development program. The Company currently owns all development and marketing rights to its drug candidate. Pursuant to the Agreement and Plan of Merger entered into on April 11, 2016, between our predecessor entities, LAT Pharma LLC and NanoAntibiotics, Inc., BioVie is obligated to pay a low single digit royalty on net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma Members, PharmaIn Corporation, and The Barrett Edge, Inc. In neurodegenerative disease, BioVie acquired the biopharmaceutical assets of NeurMedix, Inc. (“NeurMedix”), a privately held clinical-stage pharmaceutical company, in June 2021 (See Note 5 Related Party Transactions ). On January 20, 2022, the Company initiated by treating the first patient, in it’s Phase 2 study assessing NE3107’s safety and tolerability and potential pro-motoric impact in Parkinson’s disease patients. The NM201 study (NCT05083260) is a double-blind, placebo-controlled, safety, tolerability, and pharmacokinetics study in Parkinson’s Disease (PD). Participants will be treated with carbidopa/levodopa and NE3107 or placebo. Forty patients with a defined PD medication “off state” will be randomized 1:1 placebo to: active NE3107 20 mg twice daily for 28 days. Safety assessments will look at standard measures of patient health and potential for drug-drug interactions affecting L-dopa pharmacokinetics and activity. Exploratory efficacy assessments will use the Motor Disease Society Unified Parkinson’s Disease Rating (MDS-UPDRS) parts 1-3, ON/OFF Diary, and Non-Motor Symptom Scale. Topline results are expected for the NM201 study in mid-2022. Inflammation-driven insulin resistance is believed to be implicated in a broad range of serious diseases, including multiple myeloma and prostate cancer, and we plan to begin exploring these opportunities in the coming months using NE3107 or related compounds acquired in the NeurMedix asset purchase. NE3107 is patented in the United States, Australia, Canada, Europe and South Korea.

Liquidity

Liquidity	6 Months Ended
	Dec. 31, 2021
Liquidity
Liquidity	2. Liquidity The Company’s operations are subject to a number of factors that can affect its operating results and financial conditions. Such factors include, but are not limited to: the results of clinical testing and trial activities of the Company’s products, the Company’s ability to obtain regulatory approval to market its products; competition from products manufactured and sold or being developed by other companies; the price of, and demand for, Company products; the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products; and the Company’s ability to raise capital. The Company’s financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of December 31, 2021, the Company had working capital of approximately $ 26.2 million The future viability of the Company is largely dependent upon its ability to raise additional capital to finance its operations. Management expects that future sources of funding may include sales of equity, obtaining loans, or other strategic transactions. The continual widespread health emergencies or pandemics such as the coronavirus (“COVID-19”) pandemic (and its related variants), has lead to continued regional quarantines, business shutdowns, labor shortages, disruptions to supply chains, and overall economic instability. Although some jurisdictions have relaxed these measures, others have not or have reinstated them as COVID-19 cases surge and variants emerge. The duration and spread of the COVID-19 pandemic and the long-term impact of COVID-19 and its variants on the financial markets and the overall economy are highly uncertain and cannot be predicted at this time. If the financial markets and/or the overall economy are impacted for an extended period, the Company’s ability to raise funds may be materially adversely affected. In addition, the COVID-19 pandemic has created a widespread labor shortage, including a shortage of medical professionals, which may adversely impact our ability to continue or complete our clinical trials in the planned timeline. Although management continues to pursue the Company’s strategic plans, there is no assurance that the Company will be successful in obtaining sufficient financing on terms acceptable to the Company, if at all, to fund continuing operations. These circumstances raise substantial doubt on the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Significant Accounting Policies

Significant Accounting Policies	6 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Significant Accounting Policies	3. Significant Accounting Policies Basis of Presentation – Interim Financial Information These unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United State of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (the “SEC”) for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The condensed balance sheet at June 30, 2021 was derived from audited annual financial statements for the year ended June 30, 2021 but does not contain all the footnote disclosures from the annual financial statements. These unaudited interim condensed financial statements and information included under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations” should be read in conjunction with the Company’s audited financial statements for the fiscal years ended June 30, 2021 and 2020 in our Annual Report on Form 10-K filed with the SEC on August 30, 2021. For a summary of significant accounting policies, see the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2021, filed with the SEC on August 30, 2021. Certain prior period amounts have been reclassified for consistency with the current period presentation. Fair Value of Financial Instruments Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value for applicable assets and liabilities, we consider the principal or most advantageous market in which we would transact and we consider assumptions. market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. This guidance also establishes a fair value hierarchy to prioritize inputs used in measuring fair value as follows: ● Level 1: Observable inputs such as quoted prices in active markets; ● Level 2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and ● Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions Net loss per Common Share Basic net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, and convertible debentures. For the three and six months ended December 31, 2021 and 2020, such amounts were excluded from the diluted loss since their effect was considered anti-dilutive due to the net loss for the period. The table below shows the number of outstanding stock options and warrants as of December 31, 2021 and 2020: Schedule of Dilutive securities were excluded from the computation of diluted loss per share December 31, 2021 December 31, 2020 Number of Shares Number of Shares Stock Options 2,047,910 750,400 Warrants 519,763 214,665 Total 2,567,673 965,065 Recent Accounting Pronouncements The Company considers the applicability and impact of all Accounting Standards Updates (“ASU’s”). There were no recent ASUs that are expected to have a material impact on the Company’s balance sheets or statements of operations.

Intangible Assets

Intangible Assets	6 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	4. Intangible Assets The Company’s intangible assets consist of intellectual property acquired from LAT Pharma, Inc. and are amortized over their estimated useful lives. The following is a summary of the intangible assets as of December 31, 2021 and June 30, 2021: December 31, 2021 June 30, 2021 Intellectual Property $ 2,293,770 $ 2,293,770 Less Accumulated Amortization (1,312,610 ) (1,197,921 ) Intellectual Property, Net $ 981,161 $ 1,095,849 Amortization expense was $ 57,344 114,689 114,688 10 years Estimated future amortization expense is as follows: Schedule of Future expected Amortization of intangible assets Year ending June 30, 2022 (Remaining six months) $ 114,689 2023 229,377 2024 229,377 2025 229,377 2026 178,341 Intellectual Property, Net $ 981,161

Related Party Transactions

Related Party Transactions	6 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions	5. Related Party Transactions Asset Acquisition with NeurMedix On April 27, 2021, the Company entered into an Asset Purchase Agreement (“APA”) with NeurMedix and Acuitas Group Holdings, LLC (“Acuitas”), which are related party affiliates, pursuant to which the Company acquired certain assets from NeurMedix and assumed certain liabilities of NeurMedix, in exchange for consideration of cash and shares of common stock. The acquired assets include, among others, those related to certain drug candidates being developed by NeurMedix, including NE3107, a small molecule orally administered inhibitor of insulin resistance and the pathological inflammatory cascade, with a novel mechanism of action that has potential applications for treatment against Alzheimer’s Disease and Parkinson’s Disease. Subject to the terms and conditions of the APA, following the closing, the Company was potentially obligated to deliver contingent stock consideration to NeurMedix (or its successor). Previously, the Company was obligated to deliver contingent stock consideration to NeurMedix (or its successor) consisting of shares of the Company’s common stock having an aggregate value of up to $3.0 billion, subject to the Company’s achievement of certain clinical, regulatory and commercial milestones related to the drug candidates to be acquired from NeurMedix, and subject to a cap limiting each issuance of shares if such issuance would result in the beneficial ownership of NeurMedix and its affiliates exceeding 89.9999% of the Company’s issued and outstanding common stock. Pursuant to Amendment No. 1 to the APA, dated May 9, 2021, the Company is now obligated to deliver to NeurMedix (or its successor) 4.5 million shares upon the achievement of each of the four milestones set forth in the APA, for an aggregate of up to 18 million shares, subject to a cap limiting the issuance of shares if such issuance would result in the beneficial ownership of NeurMedix and its affiliates exceeding 87.5% of the Company’s issued and outstanding common stock. On June 10, 2021, and pursuant to the APA, the Company issued to Acuitas (as NeurMedix’s assignee) 8,361,308 shares of the Company’s common stock and made a cash payment of approximately $2.3 million, representing NeurMedix’s direct and documented cash expenditures to advance certain programs from March 1, 2021 through the closing date and cash payments to other third parties for expenses totaling approximately $4.0 million for due diligence, legal fees, transaction fees and the fairness opinion. Since the transaction was between entities under common control, there were no fair value adjustments of the purchased assets, and the historical cost basis of the purchased assets was zero. The total consideration paid was expensed as research and development expense at the time of the transaction. Equity Transactions with Acuitas On September 22, 2020, concurrent with the closing of the Company’s Offering, approximately $1.8 million was paid to Acuitas satisfying all amounts owed on the Debenture due September 24, 2020 held by the Company’s controlling stockholder, Acuitas. Additionally, in connection with the close of the public offering on September 22, 2020, the Company issued an aggregate of 6,909,582 During the year ended June 30, 2021, the Company received additional draws under the Debenture totaling $436,000. The total draws as of September 22, 2020 were $1.7 million and the related total number of warrants issuable at $4.00 per share of common stock was 424,750 of which 328,250 warrants had been issued. In accordance with the Debenture agreements, at September 22, 2020 upon the Company’s close of its public offering, all the warrants issued related to the debenture totaling 1,453,250 were mandatorily redeemed along with the additional 96,500 shares common stock issued to Acuitas.

Other Liabilities

Other Liabilities	6 Months Ended
	Dec. 31, 2021
Other Liabilities Disclosure [Abstract]
Other Liabilities	6. Other Liabilities Other liabilities represent retention bonus arrangements with certain employees that was recognized in August 2021 totaling $ 1,161,000

Notes Payable

Notes Payable	6 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Notes Payable	7. Notes Payable On November 30, 2021, (the “Closing Date”) the Company entered into a Loan and Security Agreement and the Supplement to the Loan and Security Agreement and Promissory Notes (together, the “Loan Agreement”) with Avenue Venture Opportunities Fund, L.P. (“AVOPI” and Avenue Venture Opportunities Fund II, L.P. (“AVOPII”) together (“Avenue”) for growth capital loans in an aggregate commitment amount of up to $20 million (the “Loan”). On the closing date, $15 million funded (“Tranche 1”) and up to $5 million will be made available to the Company on or prior to September 15, 2022, subject to the Company’s achievement of certain milestones with respect to certain of its ongoing clinical trials (“Tranche 2”). The Loan bears interest at an annual rate equal to the greater of (a) the sum of 7.00% plus the prime rate as reported in The Wall Street Journal and (b) 10.75%. The Loan is secured by a lien upon and security interest in all of the Company’s assets, including intellectual property, subject to agreed exceptions. The maturity date of the Loan is December 1, 2024. An additional growth capital loan in an amount equal to $5 million may be available (i) upon the Company’s achievement of additional milestones with respect to certain of its ongoing clinical trials (ii) upon the mutual written agreement of the Company and the Lenders each acting in its sole discretion, and (iii) subject to execution and delivery by the Company and the Lenders of amendments to the loan documents and the Warrant (as defined below) to reflect such additional loan and approval of each Lender’s investment committee (“Tranche 3”). The Loan Agreement requires monthly interest-only payments during the first eighteen months of the term of the Loan, which may be increased up to an additional six months from the end of such eighteen-month period prior to receipt of the Tranche 2 Loan. Following the interest-only period, the Company will make equal monthly payments of principal, plus accrued interest, until the Loan’s maturity date when all remaining principal and accrued interest is due. If the Company prepays the Loan, it will be required to pay (a) a prepayment fee in an amount equal to 3.0% of the principal amount of the Loan that is prepaid during the interest-only period; and (b) a prepayment fee in an amount equal to 1.0% of the principal amount of the Loan that is prepaid after the interest-only period. At the Loan’s maturity date, or on the date of the prepayment of the Loan, a final payment equal to 4.25% of the sum of (a) the Loan commitment amount under Tranche 1 and Tranche 2, plus (b) the aggregate principal amount of additional growth capital loans borrowed under Tranche 3. The Loan Agreement includes a conversion option to convert up to $5 million of the principal amount of the Loan outstanding at the option of the Lenders, into shares of the Company’s Class A common stock at a conversion price of $6.98 per share. On the Closing Date, the Company issued to the Lenders warrants to purchase 361,002 shares of Class A common stock of the Company (the “Warrants”) at an exercise price per share equal to $5.82 (the “Stock Purchase Price”). The warrants are exercisable until November 30, 2026 (the “Expiration Date”). The amount of the carrying value of the notes payable were determined by allocating portions of the outstanding principal of the notes to the fair value of the warrants of approximately $1.4 million and the fair value of the embedded conversion option of approximately $2.2 million. Accordingly, the total amount of unearned discount of approximately $3.7 million, the total direct financing cost of approximately $390,000 and premium of $850,000 are recognized on an effective interest method over term of the Loan. The adjusted effective interest rate is 25%. The carrying value of notes payable at December 31, 2021 was approximately $11.1 million, net of unearned discount of approximately $3.5 million, unamortized direct costs of approximately $376,000 and accreted premium of approximately $24,000 in the accompanying balance sheets. The total interest expense of approximately $316,000 for the three and six months ended December 31, 2021, was recognized in the accompanying statements of operations. The following is a summary of the Note Payable as of December 31, 2021 and June 30, 2021: December 31, 2021 June 30, 2021 Note Payable $ 15,000,000 $ — Less debt financing costs $ (375,900 ) — Less unearned discount $ (3,536,524 ) — Plus accretion of loan premium 23,611 — Note Payable, net of financing costs and premiums $ 11,111,187 $ — Estimated future amortization expense and accretion of premium is as follows: Unearned Discount Debt Financing Loan accretion Premium Year ending June 30, 2022 (Remaining six months) $ 800,722 $ 85,110 $ 141,667 2023 1,601,445 170,219 283,333 2024 1,023,145 108,751 283,333 2025 111,212 11,820 118,056 Total $ 3,536,524 $ 375,900 $ 826,389

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	8. Fair Value Measurements At December 31,2021 and June 30, 2021, the estimated fair value of derivative liabilities measured on a recurring basis Fair Value Measurements at December 31, 2021 Level 1 Level 2 Level 3 Total Derivative liability - Warrants $ — $ — $ 896,959 $ 896,959 Derivative liability -Conversion option — — 1,217,765 1,217,765 Total derivatives $ — $ — $ 2,114,724 $ 2,114,724 Fair Value Measurements at June 30, 2021 Level 1 Level 2 Level 3 Total Derivative liability - Warrants $ — $ — $ — $ — Derivative liability -Conversion option on convertible debenture — — — — Total derivatives $ — $ — $ — $ — The following table presents the activity for liabilities measured at fair value unobservable inputs Derivative liabilities - Warrants Derivative liability - Conversion Option on Convertible Debenture Balance at July 1, 2021 $ — $ — Additions to level 3 liabilities 1,456,512 2,213,466 Change in in fair value of level 3 liability (559,553 ) (995,701 ) Transfer in and/or out of Level 3 — — Balance at December 31, 2021 $ 896,959 $ 1,217,765 The following table presents the activity for liabilities measured at fair value unobservable inputs for the six months ended December 31, 2020: Derivative liabilities - Warrants Derivative liability - Conversion Option on Convertible Debenture Beginning balance at July 1, 2020 $ 16,411,504 $ 5,000,800 Additions to level 3 liabilities — — Change in in fair value of level 3 liability (6,054,121 ) (2,225,798 ) Transfer in and/or out of Level 3 (10,357,383 ) (2,775,002 ) Balance at December 31, 2020 $ — $ — The fair values of derivative liabilities for the warrants and conversion option at December 31, 2021 were approximately $897,000 and approximately $1.2 million, respectively. The total change in the fair value of the derivative liabilities totaled approximately $1.6 million 2021 and accordingly, was recorded in the accompanying statement of operations for the three and six months ended December 31, 2021. The assumptions used in the Black Scholes model to value the derivative liabilities included the closing stock price of $ 4.50 5.82 5-year 1.26% 74.796% 6.98 3-year 0.97% 76.15% Derivative liability - Warrants The Company accounts for stock purchase warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreements. Under applicable accounting guidance, stock warrants that are precluded from being indexed to the Company’s own stock because of full-rachet and anti-dilution provisions or adjustments to the strike price due to an occurrence of a future event; are accounted as derivative financial instruments. The warrants issued on November 30, 2021 in connection with the Avenue loan financing were not considered to be indexed to the Company’s own stock and accordingly, recorded as a derivative liability at their fair values in the accompany balance sheets at December 31, 2021. The Black Scholes model was used to calculate the fair value of the warrant derivative to bifurcate the warrant derivative amount from the Avenue loan amount funded. The warrants are recorded at their fair values at the date of issuance and remeasured at December 31, 2021. The assumptions used for the fair value calculation at November 30, 2021 follows: the closing stock price of $ 6.44 5.82 5 year 1.14% 74.4% Embedded derivative liability – Conversion Option The embedded derivative represents the optional conversion feature of up to $5.0 million of the outstanding Avenue note amounts meets the definition of a derivative and requires bifurcation from the loan amount. The Black Scholes model was used to calculate the fair value of the embedded derivative to bifurcate the embedded derivative amount representing the conversion option from the Avenue loan amount funded. The assumption used for the fair value calculation at November 30, 2021 follows: the closing stock price of $ 6.44 6.98 3 year 0.81% 76.85%

Equity Transactions

Equity Transactions	6 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Equity Transactions	9. Equity Transactions Stock Options The following table summarizes the activity relating to the Company’s stock options Options Weighted-Average Exercise Price Weighted Remaining Average Contractual Term Aggregate Intrinsic Value Outstanding at June 30, 2021 755,200 $ 4.34 4.4 $ 2,569,232 Granted 1,365,835 7.74 5.0 — Options Forfeited (73,125 ) (13.91 ) — — Outstanding at December 31, 2021 2,047,910 $ 9.79 4.4 $ 15,840 Exercisable at December 31, 2021 509,667 $ 9.36 4.2 $ 15,840 The fair value of each option grant on the date of grant is estimated using the Black-Scholes option. The pricing model reflects the following weighted-average assumptions December 31, 2021 December 31, 2020 Expected life of options (In years) 5 5 Expected volatility 74.96 % 77.29 % Risk free interest rate 0.8 % 0.4 % Dividend Yield 0 % 0 % Expected volatility is based on the historical volatilities of the daily closing price of the common stock of three comparable companies and the expected life of options is based on historical data with respect to employee exercise periods. The Company accounts for forfeitures as they are incurred. The Company recorded stock option-based compensation expense of $1,147,422 and $1,536,929 for three-month periods ended December 31, 2021 and 2020, respectively; and of $3,074,384 and $1,536,929 for six-month periods ended December 31, 2021 and 2020, respectively. As of December 31, 2021, there was approximately $ 5.7 million The following is a summary of stock options outstanding and exercisable by exercise price Exercise Price Outstanding Weighted Average Contract Life Exercisable $ 2.80 7,200 3.1 7,200 $ 3.75 4,800 2.1 4,800 $ 6.25 1,600 1.8 1,600 $ 7.50 25,600 4.1 25,600 $ 7.74 1,365,835 4.6 273,167 $ 8.75 1,600 2.3 1,600 $ 9.54 800 3.8 800 $ 9.90 800 3.8 800 $ 12.50 4,000 1.1 4,000 $ 13.91 618,475 4.0 172,900 $ 25.00 1,600 0.8 1,600 $ 26.25 4,400 0.3 4,400 $ 27.50 800 0.2 800 $ 28.75 1,600 0.6 1,600 $ 31.25 4,000 — 4,000 $ 42.09 4,800 4.1 4,800 2,047,910 509,667 Stock Warrants The following table summarizes warrant activity Number of Shares Weighted Average Exercise Price Weighted Average Remaining Life (Years) Aggregate Intrinsic Value Outstanding and exercisable at June 30, 2021 158,761 $ 10.37 3.1 $ 1,765,437 Granted 361,002 $ 5.82 5.0 $ — Exercised — $ — — $ — Outstanding and exercisable at December 31, 2021 519,763 $ 7.21 4.2 $ 247,124 Of the above warrants, 9,391 expire in the fiscal year ending June 30, 2022, 4,815 expire in the fiscal year ending June 30, 2023, 2,714 expire in the fiscal year ending June 30, 2025, and 502,843 expire in the fiscal year ending June 30, 2026. Issuance of common stock for cash On August 11, 2021, the Company closed a registered public offering issuing 2,500,000 of its Class A common stock at $8.00 per share, resulting in net proceeds to the Company of approximately $17.8 million, net of issuance costs of approximately $2.2 million. On September 24, 2021, the Company issued 92,000 of its Class A common stock at $8.00 per share in connection with the underwriters’ exercise of its over-allotment option in for the August 2021 registered public offering, resulting in net proceeds to the Company of approximately $707,000, net of issuance cost of approximately $29,000. Issuance of Shares for Services On August 20, 2021, the Company awarded 58,759 restricted stock units (“RSUs”) to the President and CEO under the Company’s 2019 Omnibus Incentive Equity Plan (the “2019 Omnibus Plan”) as his salary for the period from April 27, 2021, the date of his appointment, through December 31, 2021. The number of RSUs awarded was based on a prorated annual base salary of $600,000 at a 10% discount to the grant date fair value of $7.74 per share of the Company’s common stock. Each RSU awarded the to the CEO entitles him to receive one share of common stock upon vesting. A total of 15,339 RSUs (representing the pro rata portion of the RSU award for the period from April 27, 2021 to June 30, 2021) vested at the grant date, 21,710 vested at September 30, 2021 and 21,710 vested at December 31, 2021. Accordingly, as of December 31, 2021, 58,759 shares of common had been issued to the CEO. The Company recorded stock-based compensation expense related to these RSUs of $97,695 and $384, 454 for three and six month periods ended December 31, 2021, respectively. Issuance of Stock Options On August 20, 2021, the Company granted, under the 2019 Omnibus Plan, stock options to purchase 1,365,835 shares of common stock to the executive management team. Twenty percent (20%) of the shares underlying the options awarded vested on the grant date, and the remaining 80% vest equally over a 5-year period, on the first, second, third, fourth and fifth anniversary of the grant date. The option price per share is $7.74 per share, the grant date fair value, and the options terminate on the tenth anniversary of the grant date. Forfeiture of Stock Options On August 27, 2021, the Chief Executive Officer forfeited unvested stock options to purchase up to 73,125 shares of common stock that were previously granted to him as compensation as an independent director of the board.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	10. Commitments and Contingencies Office Lease From July 1, 2019 to October 31, 2021, the Company paid monthly rent of $1,000 to Acuitas for its headquarter office at 2120 Colorado Avenue Suite 230, Santa Monica, CA 90404. Effective November 1, 2021, the Company relocated its headquarters to Nevada at 9120 Double Diamond Parkway, Suite 1400, Reno Nevada 89521. On June 1, 2021, the Company assumed a NeurMedix office lease that was extended to February 2022 at 6165 Greenwich Dr Suite 150, San Diego, CA 92122. The lease agreement requires monthly payments of $8,782. The Company will be relocating to 5090 Shoreham Place, San Diego, CA 92122 on February 26, 2022, its new office space, (“New Office”). The Company on December 21, 2021, entered into a lease agreement for the New Office. The term of the lease is for 40 months commencing on March 1, 2022. Monthly base rate of $4,175 begins on May 1, 2022, with three percent increases at the end of each 12 month period. Challenge to US Patent On April 30, 2018, we received notice that Mallinckrodt had petitioned the U.S. Patent and Trademark Office (“USPTO”) to institute an Inter Partes Review (“IPR”) of our U.S. Patent No. 9,655,945 titled “Treatment of Ascites” (the “’945 patent”). On November 13, 2019, the Patent Trial and Appeal Board of USPTO issued a written decision in the IPR from which no appeal was taken. The decision revoked all of the claims of the patent as lacking novelty or as obvious. This ruling is unrelated to the Company’s Orphan drug designations for ascites and hepatorenal syndrome (“HRS”), which remain unchanged. An Orphan drug that is first-to-market typically receives 7 years of market exclusivity in the United States for the designated use(s). In addition, the ruling does not affect the Company’s rights in its pending patent application directed to proprietary liquid formulations of terlipressin for use in its planned Phase 2 and Phase 3 trials, subject to FDA review and authorization, which could eventually provide up to 20 years of patent coverage in each country in which the Company seeks patent protection, such as the United States, if a patent issues from a patent application according to the patent laws of each issuing count. Royalty Agreements Pursuant to the Agreement and Plan of Merger entered into on April 11, 2016, between our predecessor entities, LAT Pharma LLC and NanoAntibiotics, Inc., BioVie is obligated to pay a low single digit royalty on net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma Members, PharmaIn Corporation, and The Barrett Edge, Inc. Pursuant to the Technology Transfer Agreement entered into on July 25, 2016 between BioVie and the University of Padova (Italy), BioVie is obligated to pay a low single digit royalty on net sales of all terlipressin products covered by US patent no. 9,655,645 and any future foreign issuances capped at a maximum of $200,000 per year.

Employee Benefit Plan

Employee Benefit Plan	6 Months Ended
	Dec. 31, 2021
Employee Benefit Plan
Employee Benefit Plan	11. Employee Benefit Plan On August 1, 2021, the Company began sponsoring an employee benefit plan subject to Section 401(K) of the Internal Revenue Service Code (the “401K Plan”) pursuant to which, all employees meeting eligibility requirements are able to participate. Subject to certain limitations in the Internal Revenue Code, eligible employees are permitted to make contributions to the 401K Plan on a pre-tax salary reduction basis and the Company will match 5% of the first 5% of an employee’s contributions to the 401K Plan. For the three and six months ended December 31, 2021, the Company’s contributions to the 401K Plan totaled approximately $ 22,800 46,600

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	6 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation – Interim Financial Information	Basis of Presentation – Interim Financial Information These unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United State of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (the “SEC”) for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The condensed balance sheet at June 30, 2021 was derived from audited annual financial statements for the year ended June 30, 2021 but does not contain all the footnote disclosures from the annual financial statements. These unaudited interim condensed financial statements and information included under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations” should be read in conjunction with the Company’s audited financial statements for the fiscal years ended June 30, 2021 and 2020 in our Annual Report on Form 10-K filed with the SEC on August 30, 2021. For a summary of significant accounting policies, see the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2021, filed with the SEC on August 30, 2021. Certain prior period amounts have been reclassified for consistency with the current period presentation.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value for applicable assets and liabilities, we consider the principal or most advantageous market in which we would transact and we consider assumptions. market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. This guidance also establishes a fair value hierarchy to prioritize inputs used in measuring fair value as follows: ● Level 1: Observable inputs such as quoted prices in active markets; ● Level 2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and ● Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions
Net loss per Common Share	Net loss per Common Share Basic net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, and convertible debentures. For the three and six months ended December 31, 2021 and 2020, such amounts were excluded from the diluted loss since their effect was considered anti-dilutive due to the net loss for the period. The table below shows the number of outstanding stock options and warrants as of December 31, 2021 and 2020: Schedule of Dilutive securities were excluded from the computation of diluted loss per share December 31, 2021 December 31, 2020 Number of Shares Number of Shares Stock Options 2,047,910 750,400 Warrants 519,763 214,665 Total 2,567,673 965,065
Recent Accounting Pronouncements	Recent Accounting Pronouncements The Company considers the applicability and impact of all Accounting Standards Updates (“ASU’s”). There were no recent ASUs that are expected to have a material impact on the Company’s balance sheets or statements of operations.

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	6 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Schedule of Dilutive securities were excluded from the computation of diluted loss per share	The table below shows the number of outstanding stock options and warrants as of December 31, 2021 and 2020: Schedule of Dilutive securities were excluded from the computation of diluted loss per share
Significant Accounting Policies	December 31, 2021 December 31, 2020 Number of Shares Number of Shares Stock Options 2,047,910 750,400 Warrants 519,763 214,665 Total 2,567,673 965,065

Intangible Assets (Tables)

Intangible Assets (Tables)	6 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
The following is a summary of the intangible assets as of December 31, 2021 and June 30, 2021:	The following is a summary of the intangible assets as of December 31, 2021 and June 30, 2021:
Intangible Assets	December 31, 2021 June 30, 2021 Intellectual Property $ 2,293,770 $ 2,293,770 Less Accumulated Amortization (1,312,610 ) (1,197,921 ) Intellectual Property, Net $ 981,161 $ 1,095,849
Schedule of Future expected Amortization of intangible assets	Estimated future amortization expense is as follows: Schedule of Future expected Amortization of intangible assets
Intangible Assets (Details 2)	Year ending June 30, 2022 (Remaining six months) $ 114,689 2023 229,377 2024 229,377 2025 229,377 2026 178,341 Intellectual Property, Net $ 981,161

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
estimated fair value of derivative liabilities measured on a recurring basis	At December 31,2021 and June 30, 2021, the estimated fair value of derivative liabilities measured on a recurring basis
Fair Value Measurements	Fair Value Measurements at December 31, 2021 Level 1 Level 2 Level 3 Total Derivative liability - Warrants $ — $ — $ 896,959 $ 896,959 Derivative liability -Conversion option — — 1,217,765 1,217,765 Total derivatives $ — $ — $ 2,114,724 $ 2,114,724 Fair Value Measurements at June 30, 2021 Level 1 Level 2 Level 3 Total Derivative liability - Warrants $ — $ — $ — $ — Derivative liability -Conversion option on convertible debenture — — — — Total derivatives $ — $ — $ — $ —
activity for liabilities measured at fair value unobservable inputs	The following table presents the activity for liabilities measured at fair value unobservable inputs Derivative liabilities - Warrants Derivative liability - Conversion Option on Convertible Debenture Balance at July 1, 2021 $ — $ — Additions to level 3 liabilities 1,456,512 2,213,466 Change in in fair value of level 3 liability (559,553 ) (995,701 ) Transfer in and/or out of Level 3 — — Balance at December 31, 2021 $ 896,959 $ 1,217,765 The following table presents the activity for liabilities measured at fair value unobservable inputs for the six months ended December 31, 2020: Derivative liabilities - Warrants Derivative liability - Conversion Option on Convertible Debenture Beginning balance at July 1, 2020 $ 16,411,504 $ 5,000,800 Additions to level 3 liabilities — — Change in in fair value of level 3 liability (6,054,121 ) (2,225,798 ) Transfer in and/or out of Level 3 (10,357,383 ) (2,775,002 ) Balance at December 31, 2020 $ — $ —
[custom:DisclosureFairValueMeasurementsDetails2Abstract]	Derivative liabilities - Warrants Derivative liability - Conversion Option on Convertible Debenture Balance at July 1, 2021 $ — $ — Additions to level 3 liabilities 1,456,512 2,213,466 Change in in fair value of level 3 liability (559,553 ) (995,701 ) Transfer in and/or out of Level 3 — — Balance at December 31, 2021 $ 896,959 $ 1,217,765 The following table presents the activity for liabilities measured at fair value unobservable inputs for the six months ended December 31, 2020: Derivative liabilities - Warrants Derivative liability - Conversion Option on Convertible Debenture Beginning balance at July 1, 2020 $ 16,411,504 $ 5,000,800 Additions to level 3 liabilities — — Change in in fair value of level 3 liability (6,054,121 ) (2,225,798 ) Transfer in and/or out of Level 3 (10,357,383 ) (2,775,002 ) Balance at December 31, 2020 $ — $ —

Equity Transactions (Tables)

Equity Transactions (Tables)	6 Months Ended
	Dec. 31, 2021
Equity [Abstract]
activity relating to the Company’s stock options	The following table summarizes the activity relating to the Company’s stock options
Equity Transactions	Options Weighted-Average Exercise Price Weighted Remaining Average Contractual Term Aggregate Intrinsic Value Outstanding at June 30, 2021 755,200 $ 4.34 4.4 $ 2,569,232 Granted 1,365,835 7.74 5.0 — Options Forfeited (73,125 ) (13.91 ) — — Outstanding at December 31, 2021 2,047,910 $ 9.79 4.4 $ 15,840 Exercisable at December 31, 2021 509,667 $ 9.36 4.2 $ 15,840
The pricing model reflects the following weighted-average assumptions	The fair value of each option grant on the date of grant is estimated using the Black-Scholes option. The pricing model reflects the following weighted-average assumptions
Equity Transactions (Details 2)	December 31, 2021 December 31, 2020 Expected life of options (In years) 5 5 Expected volatility 74.96 % 77.29 % Risk free interest rate 0.8 % 0.4 % Dividend Yield 0 % 0 %
summary of stock options outstanding and exercisable by exercise price	The following is a summary of stock options outstanding and exercisable by exercise price
Equity Transactions (Details 3)	Exercise Price Outstanding Weighted Average Contract Life Exercisable $ 2.80 7,200 3.1 7,200 $ 3.75 4,800 2.1 4,800 $ 6.25 1,600 1.8 1,600 $ 7.50 25,600 4.1 25,600 $ 7.74 1,365,835 4.6 273,167 $ 8.75 1,600 2.3 1,600 $ 9.54 800 3.8 800 $ 9.90 800 3.8 800 $ 12.50 4,000 1.1 4,000 $ 13.91 618,475 4.0 172,900 $ 25.00 1,600 0.8 1,600 $ 26.25 4,400 0.3 4,400 $ 27.50 800 0.2 800 $ 28.75 1,600 0.6 1,600 $ 31.25 4,000 — 4,000 $ 42.09 4,800 4.1 4,800 2,047,910 509,667
summarizes warrant activity	The following table summarizes warrant activity
Equity Transactions (Details 4)	Number of Shares Weighted Average Exercise Price Weighted Average Remaining Life (Years) Aggregate Intrinsic Value Outstanding and exercisable at June 30, 2021 158,761 $ 10.37 3.1 $ 1,765,437 Granted 361,002 $ 5.82 5.0 $ — Exercised — $ — — $ — Outstanding and exercisable at December 31, 2021 519,763 $ 7.21 4.2 $ 247,124

Liquidity (Details Narrative)

Liquidity (Details Narrative)	Dec. 31, 2021USD ($)
Liquidity
[custom:WorkingCapital-0]	$ 26,200,000

Significant Accounting Polici_4

Significant Accounting Policies (Details) - shares	6 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Offsetting Assets [Line Items]
Total	2,567,673	965,065
Equity Option [Member]
Offsetting Assets [Line Items]
Total	2,047,910	750,400
Warrant [Member]
Offsetting Assets [Line Items]
Total	519,763	214,665

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	Dec. 31, 2021	Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Intellectual Property	$ 2,293,770	$ 2,293,770
Less Accumulated Amortization	(1,312,610)	(1,197,921)
Intellectual Property, Net	$ 981,161	$ 1,095,849

Intangible Assets (Details 2)

Intangible Assets (Details 2) - USD ($)	Dec. 31, 2021	Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Year ending June 30, 2022 (Remaining six months)	$ 114,689
2023	229,377
2024	229,377
2025	229,377
2026	178,341
Intellectual Property, Net	$ 981,161	$ 1,095,849

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of Intangible Assets	$ 57,344	$ 57,344	$ 114,689	$ 114,688
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life			10 years

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - shares	Dec. 31, 2021	Jun. 30, 2021	Sep. 22, 2020
Related Party Transaction [Line Items]
Common Stock, Shares, Issued	24,984,083	22,333,324
Acuitas Group Holdings L L C [Member]
Related Party Transaction [Line Items]
Common Stock, Shares, Issued			6,909,582

Other Liabilities (Details Narr

Other Liabilities (Details Narrative)	Dec. 31, 2021USD ($)
Other Liabilities Disclosure [Abstract]
Accrued Bonuses, Current	$ 1,161,000

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($)	Dec. 31, 2021	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total derivatives	$ 2,114,724
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total derivatives
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total derivatives
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total derivatives	2,114,724
Derivative Liability Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total derivatives	896,959
Derivative Liability Warrants [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total derivatives
Derivative Liability Warrants [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total derivatives
Derivative Liability Warrants [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total derivatives	896,959			$ 16,411,504
Derivative Liability Conversion Option On Convertible Debenture [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total derivatives	1,217,765
Derivative Liability Conversion Option On Convertible Debenture [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total derivatives
Derivative Liability Conversion Option On Convertible Debenture [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total derivatives
Derivative Liability Conversion Option On Convertible Debenture [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total derivatives	$ 1,217,765			$ 5,000,800

Fair Value Measurements (Deta_2

Fair Value Measurements (Details 2) - USD ($)	6 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning balance at July 1, 2020
Balance at December 31, 2020	2,114,724
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning balance at July 1, 2020
Balance at December 31, 2020	2,114,724
Derivative Liability Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning balance at July 1, 2020
Balance at December 31, 2020	896,959
Derivative Liability Warrants [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning balance at July 1, 2020		$ 16,411,504
Additions to level 3 liabilities	1,456,512
Change in in fair value of level 3 liability	(559,553)	(6,054,121)
Transfer in and/or out of Level 3		(10,357,383)
Balance at December 31, 2020	896,959
Derivative Liability Conversion Option On Convertible Debenture [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning balance at July 1, 2020
Balance at December 31, 2020	1,217,765
Derivative Liability Conversion Option On Convertible Debenture [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning balance at July 1, 2020		5,000,800
Additions to level 3 liabilities	2,213,466
Change in in fair value of level 3 liability	(995,701)	(2,225,798)
Transfer in and/or out of Level 3		(2,775,002)
Balance at December 31, 2020	$ 1,217,765

Fair Value Measurements (Deta_3

Fair Value Measurements (Details Narrative) - $ / shares	5 Months Ended	6 Months Ended
	Nov. 30, 2021	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate		0.80%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate		74.96%
Derivative Liability [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Share Price		$ 4.50
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price		$ 5.82
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term		5 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate		1.26%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate		74.796%
Embedded Derivative Liability [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price		$ 6.98
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term		3 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate		0.97%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate		76.15%
Derivative Liability Warrants [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Share Price	$ 6.44
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price	$ 5.82
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	5 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.14%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	74.40%
Embedded Derivative Liability Conversion Option [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Share Price	$ 6.44
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price	$ 6.98
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	3 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	0.81%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	76.85%

Equity Transactions (Details)

Equity Transactions (Details)	6 Months Ended
	Dec. 31, 2021USD ($)$ / sharesshares
Offsetting Assets [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance	2,047,910
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	509,667
Equity Option [Member]
Offsetting Assets [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance	755,200
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 4.34
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	4 years 8 months 24 days
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding | $	$ 2,569,232
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	1,365,835
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares	$ 7.74
Weighted Average Contractual Term, Granted (in Years)	5 years
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested | $
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	(73,125)
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | $ / shares	$ (13.91)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value | $
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance	2,047,910
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance | $ / shares	$ 9.79
[custom:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4]	4 years 8 months 24 days
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding | $	$ 15,840
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	509,667
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price | $ / shares	$ 9.36
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term	4 years 2 months 12 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value | $	$ 15,840

Equity Transactions (Details 2)

Equity Transactions (Details 2)	6 Months Ended	12 Months Ended
	Dec. 31, 2021	Jun. 30, 2021
Offsetting Assets [Line Items]
Expected volatility	74.96%
Risk free interest rate	0.80%
Dividend Yield	0.00%
Equity Option [Member]
Offsetting Assets [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	5 years	5 years
Expected volatility		77.29%
Risk free interest rate		0.40%
Dividend Yield		0.00%

Equity Transactions (Details 3)

Equity Transactions (Details 3)	6 Months Ended
	Dec. 31, 2021$ / sharesshares
Offsetting Assets [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	2,047,910
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	509,667
Stock Option 1 [Member]
Offsetting Assets [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares	$ 2.80
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	7,200
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	7,200
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	3 years 1 month 6 days
Stock Option 2 [Member]
Offsetting Assets [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares	$ 3.75
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	4,800
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	4,800
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	2 years 1 month 6 days
Stock Option 3 [Member]
Offsetting Assets [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares	$ 6.25
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	1,600
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	1,600
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	1 year 9 months 18 days
Stock Option 4 [Member]
Offsetting Assets [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares	$ 7.50
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	25,600
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	25,600
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	4 years 1 month 6 days
Stock Option 5 [Member]
Offsetting Assets [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares	$ 7.74
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	1,365,835
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	273,167
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	4 years 7 months 6 days
Stock Option 6 [Member]
Offsetting Assets [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares	$ 8.75
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	1,600
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	1,600
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	2 years 3 months 18 days
Stock Option 7 [Member]
Offsetting Assets [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares	$ 9.54
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	800
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	800
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	3 years 9 months 18 days
Stock Option 8 [Member]
Offsetting Assets [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares	$ 9.90
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	800
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	800
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	3 years 9 months 18 days
Stock Option 9 [Member]
Offsetting Assets [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares	$ 12.50
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	4,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	4,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	1 year 1 month 6 days
Stock Option 10 [Member]
Offsetting Assets [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares	$ 13.91
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	618,475
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	172,900
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	4 years
Stock Option 11 [Member]
Offsetting Assets [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares	$ 25
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	1,600
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	1,600
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	9 months 18 days
Stock Option 12 [Member]
Offsetting Assets [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares	$ 26.25
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	4,400
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	4,400
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	3 months 18 days
Stock Option 13 [Member]
Offsetting Assets [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares	$ 27.50
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	800
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	800
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	2 months 12 days
Stock Option 14 [Member]
Offsetting Assets [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares	$ 28.75
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	1,600
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	1,600
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	7 months 6 days
Stock Option 15 [Member]
Offsetting Assets [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares	$ 31.25
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	4,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	4,000
Stock Option 16 [Member]
Offsetting Assets [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares	$ 42.09
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	4,800
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	4,800
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	4 years 1 month 6 days

Equity Transactions (Details 4)

Equity Transactions (Details 4) - Warrant [Member]	6 Months Ended
	Dec. 31, 2021USD ($)$ / sharesshares
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Beginning Balance	158,761
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value, Beginning Balance | $ / shares	$ 10.37
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms	3 years 1 month 6 days
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding | $	$ 1,765,437
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	361,002
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Intrinsic Value, Amount Per Share | $ / shares	$ 5.82
[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantedContractualTerms]	5 years
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance	519,763
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value, Ending Balance | $ / shares	$ 7.21
[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms2]	4 years 2 months 12 days
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding | $	$ 247,124

Equity Transactions (Details Na

Equity Transactions (Details Narrative)	Jun. 30, 2021USD ($)
Equity Option [Member] | Director [Member]
Offsetting Assets [Line Items]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	$ 5,700,000

Employee Benefit Plan (Details

Employee Benefit Plan (Details Narrative) - USD ($)	3 Months Ended	6 Months Ended
	Dec. 31, 2021	Dec. 31, 2021
Employee Benefit Plan
Defined Benefit Plan, Plan Assets, Contributions by Employer	$ 22,800	$ 46,600